Vivaldi Capital Management LLC lifted its stake in Editas Medicine (NASDAQ:EDIT) by 39.6% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 10,570 shares of the company’s stock after purchasing an additional 3,000 shares during the quarter. Vivaldi Capital Management LLC’s holdings in Editas Medicine were worth $350,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Global Thematic Partners LLC increased its holdings in Editas Medicine by 8.7% in the fourth quarter. Global Thematic Partners LLC now owns 614,052 shares of the company’s stock worth $18,869,000 after buying an additional 49,011 shares during the last quarter. Carnegie Capital Asset Management LLC acquired a new position in Editas Medicine in the fourth quarter worth approximately $1,452,000. Nisa Investment Advisors LLC increased its holdings in Editas Medicine by 221.6% in the fourth quarter. Nisa Investment Advisors LLC now owns 71,400 shares of the company’s stock worth $2,194,000 after buying an additional 49,200 shares during the last quarter. D.A. Davidson & CO. acquired a new position in Editas Medicine in the fourth quarter worth approximately $267,000. Finally, Creative Planning increased its holdings in Editas Medicine by 155.5% in the fourth quarter. Creative Planning now owns 23,525 shares of the company’s stock worth $723,000 after buying an additional 14,318 shares during the last quarter. 62.98% of the stock is owned by institutional investors and hedge funds.
A number of research firms recently commented on EDIT. CLSA began coverage on Editas Medicine in a report on Tuesday, February 13th. They issued an “underperform” rating on the stock. Barclays increased their price objective on Editas Medicine from $28.00 to $46.00 and gave the stock an “overweight” rating in a report on Wednesday, March 7th. Morgan Stanley restated an “equal weight” rating and issued a $43.00 price objective (up previously from $28.00) on shares of Editas Medicine in a report on Wednesday, March 14th. Zacks Investment Research upgraded Editas Medicine from a “sell” rating to a “hold” rating in a report on Friday, March 9th. Finally, Chardan Capital dropped their price objective on Editas Medicine from $72.50 to $55.00 and set a “buy” rating on the stock in a report on Tuesday. One research analyst has rated the stock with a sell rating, six have issued a hold rating and six have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $46.14.
Shares of Editas Medicine opened at $37.06 on Thursday, MarketBeat Ratings reports. Editas Medicine has a 12 month low of $36.00 and a 12 month high of $37.13. The company has a debt-to-equity ratio of 0.13, a quick ratio of 11.71 and a current ratio of 11.71. The company has a market cap of $1.72 billion, a price-to-earnings ratio of -12.44 and a beta of 3.62.
Editas Medicine (NASDAQ:EDIT) last announced its quarterly earnings results on Thursday, May 3rd. The company reported ($0.67) EPS for the quarter, beating the consensus estimate of ($0.82) by $0.15. Editas Medicine had a negative return on equity of 58.73% and a negative net margin of 707.98%. The company had revenue of $3.90 million for the quarter, compared to the consensus estimate of $4.04 million. During the same quarter last year, the company posted ($0.85) earnings per share. The company’s revenue for the quarter was up 473.5% compared to the same quarter last year. sell-side analysts anticipate that Editas Medicine will post -3 earnings per share for the current fiscal year.
In other Editas Medicine news, CFO Andrew A. F. Hack sold 18,000 shares of the stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $34.21, for a total transaction of $615,780.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Katrine Bosley sold 8,333 shares of the stock in a transaction that occurred on Tuesday, May 1st. The shares were sold at an average price of $31.95, for a total value of $266,239.35. Following the transaction, the insider now owns 1,301,965 shares in the company, valued at approximately $41,597,781.75. The disclosure for this sale can be found here. In the last quarter, insiders have sold 98,133 shares of company stock worth $3,617,673. Corporate insiders own 19.40% of the company’s stock.
Editas Medicine Company Profile
Editas Medicine, Inc operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. The company develops a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments.
Want to see what other hedge funds are holding EDIT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Editas Medicine (NASDAQ:EDIT).
Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.